CYTE - Key Persons
Job Titles:
- Director
- Chairman of the Court
- Member of the Science Board to the FDA
Annalisa Jenkins, M.B.B.S., F.R.C.P. serves as a member of the Perspectum Ltd. board of directors. Dr Jenkins also serves as Chairman of the court of the London School of Hygiene and Tropical Medicine. Dr Jenkins previously served as the Chief Executive Officer of PlaqueTec Ltd. and was previously the Chief Executive Officer and a member of the board of directors of Dimension Therapeutics, Inc. Dr Jenkins previously served as Executive Vice President, Head of Global Research and Development for Merck Serono Pharmaceuticals. Previously, she served as Merck Serono's Executive Vice President, Global Development and Medical, and was a member of Merck Serono's Executive Committee. Prior to that, Dr Jenkins pursued a 15-year career at Bristol-Myers Squibb Company, where she was a Senior Vice President and Head of Global Medical Affairs.
Dr Jenkins is currently a committee member of the science board to the FDA, the Court of the London School of Hygiene and Tropical Medicine and is a non-executive director of Genomics England and AgeX Therapeutics, INC. Dr Jenkins serves on the board of directors of Affimed N.V., AVROBIO, Inc., Compass Pathways plc, Oncimmune.
Dr Jenkins received an M.B.B.S. in medicine from St. Bartholomew's Hospital at the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service. Earlier in her career, Dr Jenkins served as a medical officer in the British Royal Navy. Dr Jenkins is a Fellow of the Royal College of Physicians in London.
Job Titles:
- Director
- Chief Medical Officer at Actimed Therapeutics
Frank Misselwitz is currently Chief Medical Officer at Actimed Therapeutics. He was the Corporate Vice President and Head of Cardiovascular Development at Bayer Pharma AG for 20 years.
After receiving his MD and an MSc in medical biophysics in 1981, Dr Misselwitz earned his PhD in 1984. He has worked in the thrombosis field for over 30 years, initially as an active physician and director of the Haemostasis Laboratory at the Institute for Cardiovascular Research of the Academy of Sciences in Berlin, and later at various pharmaceutical companies.
He has been responsible for the worldwide clinical development of rivaroxaban (Xarelto®) since 2002. He was involved in the planning and execution of the phase II and III clinical studies, and is currently heavily involved in the planning and execution of late life cycle studies. In 2005 he became Vice President and Head of the Therapeutic Area Cardiovascular and Coagulation. Under his leadership recently Adempas® (riociguat) was successfully developed and approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Gloria Kayani is the Chief Executive Officer, with overall responsibility for creating, planning, implementing and integrating the strategic direction of CYTE.
Ms Kayani has over 25 years of experience in Pharmaceutical R&D, Medical Affairs and academic research, responsible for the strategic oversight and delivery of projects spanning all phases of clinical research. This includes 15 years in various leadership roles in clinical development at Glaxo SmithKline and Roche, managing cross functional and international clinical teams. She was a member of many clinical development teams for key Roche drugs. As Head of the Clinical Projects Group at Roche, she oversaw the management of 144 global randomised clinical trials, investigator initiated trials, early access programmes, non-interventional programmes and individual patient supply programmes.
From October 2012 to January 2024, as Chief Operating Officer and Deputy Director of CYTE's academic partner, the Thrombosis Research Institute (TRI), Ms Kayani was responsible for implementing and delivering TRI's extensive, international clinical and science research programmes. She worked closely with global experts and key opinion leaders in the thrombosis and cardiovascular medicine fields to ensure TRI delivered high quality research.
Karen Pieper has over 30 years of experience in vascular research, randomised clinical trials and observational data analysis. She served as the Independent Lead Statistician and as an Associate Director of Statistics while at the Duke Clinical Research Institute (DCRI). She has taught research concepts to industry leads and clinicians internationally. The annual Karen Pieper Award for Research Support was developed by the DCRI fellowship program in her honour.
She served as a member of the American Statistical Association Committee on Applied Statisticians and as a member of the Committee on Ethical Practices. Ms Pieper has served as the independent voting member for multiple DSMBs and is currently a member of the executive committee for a network of large trials.
She has overseen the statistical aspects of clinical programmes, through the publication of over 100 manuscripts within a trial in some cases. In addition to clinical trials, registries and publications, Ms Pieper has extensive experience combining studies for patient level meta-analyses and has been involved in the creation of data warehouses of the mega-trials with a common clinical theme.
Job Titles:
- President of the Thrombosis Research Institute
Lord Ajay Kakkar is President of the Thrombosis Research Institute and Emeritus Professor of Surgery, University College London. He is Chairman of King's Health Partners, the Office for Strategic Coordination of Health Research, the King's Fund and UK Biobank.
He completed his medical degree at King's College London and received his PhD from Imperial College London. He has been a fellow of the Royal College of Surgeons since 1992.
His research interests include the prevention and treatment of venous and arterial thromboembolic disease and cancer-associated thrombosis. His work has made an important contribution to evaluating the potential role of antithrombotic therapy in the management of cancer patients, and he has been involved in the clinical development of direct oral anticoagulants.
Lord Kakkar was created a Life Peer in 2010 and sits on the cross benches of the House of Lords. He served as Chairman of the Judicial Appointments Commission from 2016 to 2022. He is a Knight of the British Empire and a member of His Majesty's Most Honourable Privy Council. On St George's Day 2024, he was appointed Knight Companion of the Order of the Garter (KG).